贝那普利联合吡格列酮二甲双胍片治疗代谢综合征合并高血压的临床研究
|
摘要
目的探讨贝那普利联合吡格列酮二甲双胍片治疗代谢综合征合并高血压患者的临床疗效。方法选取2016年2月至2018年2月该院门诊追踪治疗的代谢综合征合并高血压患者80例,采用随机数字表法分为对照组和观察组,每组40例。对照组给予贝那普利联合二甲双胍治疗,观察组给予贝那普利联合吡格列酮二甲双胍片治疗。比较2组患者治疗前后血压、血糖、血脂、胰岛素抵抗指数等变化情况。结果 2组患者治疗12周后血压、空腹血糖、餐后2小时血糖、胰岛素抵抗指数均明显低于治疗前,且观察组明显低于对照组,差异均有统计学意义(P<0.05);观察组三酰甘油、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇水平与治疗前比较,差异均有统计学意义(P<0.05)。结论贝那普利联合吡格列酮二甲双胍片治疗代谢综合征合并高血压临床疗效满意,值得推广应用。
Objective To investigate the clinical effect of benazepril combined with pioglitazone and metformin tablets in the treatment of metabolic syndrome complicating hypertension.Methods Eighty cases of metabolic syndrome complicating hypertension conducting outpatient follow-up therapy in this hospital from February 2016 to February 2018 were selected and divided into the observation group and control group according to the random number table method,40 cases in each group.The control group was treated with benazepril combined with metformin,while the observation group was given benazepril combined with pioglitazone and metformin tablets.The changes of blood pressure,blood lipid,blood sugar and insulin resistance(HOMA-IR)before and after treatment were compared between the two groups.Results The blood pressure,blood lipid and 2 hPG,HOMA-IR after 12-week treatment in the observation group were significantly lower than those before treatment,moreover the observation group was obviously lower than the control group,and the differences were statistically significant(P<0.05).The TG,LDL-C and HDL-C levels after treatment in the observation group had significant difference compared with those before treatment,and the difference was statistically significant(P<0.05).Conclusion Benazepril combined with pioglitazone and metformin tablets in the treatment of metabolic syndrome complicating hypertension has satisfactory clinical effect and is worth popularization and application.
Objective To investigate the clinical effect of benazepril combined with pioglitazone and metformin tablets in the treatment of metabolic syndrome complicating hypertension.Methods Eighty cases of metabolic syndrome complicating hypertension conducting outpatient follow-up therapy in this hospital from February 2016 to February 2018 were selected and divided into the observation group and control group according to the random number table method,40 cases in each group.The control group was treated with benazepril combined with metformin,while the observation group was given benazepril combined with pioglitazone and metformin tablets.The changes of blood pressure,blood lipid,blood sugar and insulin resistance(HOMA-IR)before and after treatment were compared between the two groups.Results The blood pressure,blood lipid and 2 hPG,HOMA-IR after 12-week treatment in the observation group were significantly lower than those before treatment,moreover the observation group was obviously lower than the control group,and the differences were statistically significant(P<0.05).The TG,LDL-C and HDL-C levels after treatment in the observation group had significant difference compared with those before treatment,and the difference was statistically significant(P<0.05).Conclusion Benazepril combined with pioglitazone and metformin tablets in the treatment of metabolic syndrome complicating hypertension has satisfactory clinical effect and is worth popularization and application.
引文
[1]赵峥.代谢综合征的研究进展[J].实用心脑肺血管病杂志,2011,19(1):143-144.
[2]卢伟,刘美霞,李锐,等.上海15~74岁居民代谢综合征的流行特征[J].中华预防医学杂志,2006,40(4):262-268.
[3]呼唤,骆宁,伦永志,等.代谢综合征的风险因素-高维生素饮食[J].大连大学学报,2013,34(3):91-93.
[4]BRUMBY S,CHANDRASEKARA A,MCCOOMBE S,et al.Cardiovascular risk factors and psychological distress in Australian farming communities[J].Aust J Rural Health,2012,20(3):131-137.
[5]中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志,2004,12(3):156-161.
[6]陈叶海,张志伟.吡格列酮联合二甲双胍治疗2型糖尿病患者临床疗效及安全性分析[J].锦州医科大学学报,2017,38(5):28-31.
[7]郭珍,蔡卫平,杜亚平.吡格列酮联合二甲双胍治疗对老年2型糖尿病患者HbA1c、血脂及胰岛素敏感性的影响[J].中国老年学杂志,2018,38(4):816-818.
[8]庄勤文,叶定村,肖招娣.吡格列酮治疗老年2型糖尿病并高血压的可行性及安全性[J].中国现代药物应用,2016,10(18):145-147.
[9]颜淑蓉.吡格列酮的临床安全性评述[J].丽水学院学报,2013,35(2):28-32.
[10]MIETTOLA J,VILJANEN AM.A salutogenic approach to prevention of metabolic syndrome:a mixed methods population study[J].Scand J Prim Health Care,2014,32(4):217-225.
[11]SULTANA N,ARAYNE MS,SHAFI N,et al.Development and validation of new assay method for the simultaneous analysis of diltiazem,metformin,pioglitazone and rosiglitazone by RP-HPLCand its applications in pharmaceuticals and human serum[J].JChromatogr Sci,2011,49(10):774-779.
[12]RAWDAREE P,DEEROCHANAWONG C,PEERAPATDIT T,et al.Efficacy and safety of generic and original pioglitazone in type 2diabetes mellitus:a multicenter,a double-blinded,randomized-controlled study[J].J Med Assoc Thai,2010,93(11):1249-1255.
[13]YANG B,FAN S,ZHI X,et al.Associations of MTHFR C677Tand MTRR A66Ggene polymorphisms with metabolic syndrome:a case-control study in Northern China[J].Int J Mol Sci,2014,15(12):21687-21702.
[14]AZK A,BURDA M,VECKA M,et al.Fatty acid composition indicates two types of metabolic syndrome Independent of clinical and laboratory parameters[J].Physiol Res,2014,63(Suppl 3):S375-385.
[2]卢伟,刘美霞,李锐,等.上海15~74岁居民代谢综合征的流行特征[J].中华预防医学杂志,2006,40(4):262-268.
[3]呼唤,骆宁,伦永志,等.代谢综合征的风险因素-高维生素饮食[J].大连大学学报,2013,34(3):91-93.
[4]BRUMBY S,CHANDRASEKARA A,MCCOOMBE S,et al.Cardiovascular risk factors and psychological distress in Australian farming communities[J].Aust J Rural Health,2012,20(3):131-137.
[5]中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中华糖尿病杂志,2004,12(3):156-161.
[6]陈叶海,张志伟.吡格列酮联合二甲双胍治疗2型糖尿病患者临床疗效及安全性分析[J].锦州医科大学学报,2017,38(5):28-31.
[7]郭珍,蔡卫平,杜亚平.吡格列酮联合二甲双胍治疗对老年2型糖尿病患者HbA1c、血脂及胰岛素敏感性的影响[J].中国老年学杂志,2018,38(4):816-818.
[8]庄勤文,叶定村,肖招娣.吡格列酮治疗老年2型糖尿病并高血压的可行性及安全性[J].中国现代药物应用,2016,10(18):145-147.
[9]颜淑蓉.吡格列酮的临床安全性评述[J].丽水学院学报,2013,35(2):28-32.
[10]MIETTOLA J,VILJANEN AM.A salutogenic approach to prevention of metabolic syndrome:a mixed methods population study[J].Scand J Prim Health Care,2014,32(4):217-225.
[11]SULTANA N,ARAYNE MS,SHAFI N,et al.Development and validation of new assay method for the simultaneous analysis of diltiazem,metformin,pioglitazone and rosiglitazone by RP-HPLCand its applications in pharmaceuticals and human serum[J].JChromatogr Sci,2011,49(10):774-779.
[12]RAWDAREE P,DEEROCHANAWONG C,PEERAPATDIT T,et al.Efficacy and safety of generic and original pioglitazone in type 2diabetes mellitus:a multicenter,a double-blinded,randomized-controlled study[J].J Med Assoc Thai,2010,93(11):1249-1255.
[13]YANG B,FAN S,ZHI X,et al.Associations of MTHFR C677Tand MTRR A66Ggene polymorphisms with metabolic syndrome:a case-control study in Northern China[J].Int J Mol Sci,2014,15(12):21687-21702.
[14]AZK A,BURDA M,VECKA M,et al.Fatty acid composition indicates two types of metabolic syndrome Independent of clinical and laboratory parameters[J].Physiol Res,2014,63(Suppl 3):S375-385.